ERAS News and Press, Erasca Inc.

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to date Favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma Randomi...

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., cha...

2024-05-23 10:04:37 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...

SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed und...

2024-05-20 01:30:00 ET Summary Takeda Pharmaceutical acquired global rights to an Alzheimer’s therapy developed by Switzerland’s AC Immune SA for $100 million upfront and up to $2.1 billion in milestone payments. Zai Lab reported China’s NMPA approved Augtyro ...

2024-05-17 10:41:13 ET More on Erasca Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript Erasca prices $160M equity offering Erasca to get $45M funding via private placement Seeking Alpha’s Quant Rating on Erasca Histo...

2024-05-17 03:10:04 ET More on Erasca Erasca to get $45M funding via private placement Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca Financial information for Erasca Read the full article on Seeking Alpha Fo...

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest ...

2024-05-09 11:56:31 ET More on Erasca Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript Erasca to get $45M funding via private placement Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca Finan...

Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketab...